Researcher in lab

Find clinical trials

Our clinical trial portfolio is one of the largest in the country. We have more than 700 clinical trials open across 30 clinical units.

Find Melbourne Sexual Health Centre research studies and clinical trials

Data source: Bayside Health Alfred Powertrials list of active trials
Updated: 1st of every month (unless a weekend)

Clear filter
663 clinical trials found
Clinical trials

TITANIA

A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease (COPD) with a History of COPD Exacerbations. (NCT05158387)

No longer recruiting

TOSCCAA - TXA

Treatment of Stroke Recurrence in CAA with Tranexamic Acid (ACTRN12624001477516)

This study is looking at whether a medicine called tranexamic acid can help reduce the risk of intracranial haemorrhage (ICH) recurrence in Cerebral Amyloid Angiopathy (CAA).
Currently recruiting

TRAILBLAZER-ALZ 2

Assessment of Safety, Tolerability, and Efficacy of LY3002813 in Early Symptomatic Alzheimer’s Disease (NCT04437511)

Currently recruiting

TRAILBLAZER-ALZ 5

Global Study to Investigate Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (NCT05508789)

Currently recruiting

TRANSFORM-2

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis (TRANSFORM-2) (NCT04468984)

No longer recruiting

Traveller WP45722

Master Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies as Assessed by Biomarker Status and Cognition

The purpose of this pre-screening study is to identify people who may be eligible for future clinical trials that test new drugs for Alzheimer’s disease (AD). Participants will be asked to perform a memory test and give a blood sample for the assessment of pTau217 blood biomarker that has been developed to help identify people who are likely to have AD. Participants will not receive any medication or therapeutic intervention in this study.
Currently recruiting

TRICS-IV

TRICS IV: Transfusion Requirements in Younger Patients Undergoing Cardiac Surgery. An international, multi-centre, randomized controlled trial to assess (NCT04754022)

Currently recruiting

TRIGS

Tranexamic acid to Reduce Infection after Gastrointestinal Surgery: the TRIGS Trial (NCT04192435)

Currently recruiting

TRIlogy-4

A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody (NCT07258511)

JNJ-79635322 (BCMAxGPRC5DxCD3) is a novel immunoglobulin G1 trispecific antibody targeting the T-cell receptor (CD3 portion) with 1 binding arm and 2 plasma cell target antigen binding domains (BCMA and GPRC5D). The primary objective is to compare the efficacy of JNJ-79635322 with an anti-BCMAxCD3 bispecific antibody (Teclistamab), based on dual primary endpoints of ORR and PFS, in participants with RRMMwho have received at least 3 prior lines of therapy including a PI, an IMiD, and an anti-CD38 antibody.
Currently recruiting

TRITON

A Feasibility Trial of Tranexamic Acid for Necrotising Soft-Tissue Infections (ACTRN12621001423808)

Currently recruiting

TRIUMPH

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index =27 kg/m^2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease. (NCT06383390)

No longer recruiting

TRONTIER 2

A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease [MCI to Mild Dementia Due to AD] (NCT07170150)

The purpose of this study is to compare the effects, good or bad, of trontinemab versus placebo on participants with AD. In this study, participants will get either trontinemab or placebo. Participants aged 50 - 90 years (inclusive) with early symptomatic AD will be eligible for inclusion. The effects of trontinemab versus placebo on clinical progression of AD will be evaluated through cognitive assessment and imaging.
Currently recruiting

TRUST

Toxicity Reduction with Urethra Sparing radiation Therapy for prostate cancer (ACTRN12625000487415)

Currently recruiting

UAE-E

A prospective pilot study of the safety and effectiveness of Uterine Artery Embolisation for the treatment of Endometriosis (ACTRN12622001301752)

Currently recruiting

UCB STACCATO ALPRAZOLAM-DB

A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures (NCT05077904)

Currently recruiting

UCB STACCATO ALPRAZOLAM-OLE

An open-label, multicenter, outpatient extension study to evaluate the safety and tolerability of Staccato Alprazolam in study participants 12 years of age and older with stereotypical prolonged seizures (NCT05076617)

Currently recruiting

V940-001

A Phase 3, Randomized, Double-Blind, Placebo- and Active-Comparator-Controlled Clinical study of Adjuvant V940 (mRNA-4157) Plus Pembrolizumab Versus Adjuvant Placebo Plus Pembrolizumab in Participants With High-Risk Stage II-IV Melanoma (NCT05933577)

No longer recruiting

VANTAGE

VANTAGE Clinical Trial: (Evaluation of TAVI using the NAVITOR valve in a Global Investigation) (NCT04788888)

No longer recruiting

VBE00001

A Phase I/II, randomized, placebo-controlled, multi-arm, dose-finding study to evaluate the safety, efficacy and immunogenicity of an Acne mRNA vaccine candidate in adults with moderate to severe acne 18 to 45 years of age (NCT06316297)

The aim of the trial is to evaluate the safety, efficacy and immunogenicity of up to 3 administrations of the Acne mRNA vaccine candidate at up to 3 dose levels (45 µg, 120 µg and 225 µg total mRNA) in adults aged 18 to 45 years with moderate to severe acne. This is a phase I/II trial, in which about 260 people will take part in this study worldwide. 36/260 will be randomized in Sentinel cohort A, 200 participants in the main cohort A and 24 participants in Sentinel cohort B.
Currently recruiting

VECTORS

An Interventional Study to Evaluate Treating to a Target of Transmural Healing in Patients with Moderately to Severely Active Crohn’s Disease [VECTORS] (NCT06257706)

Currently recruiting
30 31 32 33 34